GlassScriptPhysician profile
Celestino Pietrantoni
NPI 1689658312
$1,416.40
in general payments reported to CMS, 2019-2025
20 companies · $47.81 in 2025
The $47.81 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $682 · 2020: $121 · 2021: $271 · 2022: $123 · 2023: $83.37 · 2024: $88.35 · 2025: $47.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187 · Education: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.05 |
| Education | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $426.68 | 2019-2025 | Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $238.63 | 2019-2022 | |
| Genzyme Corporation | $130.94 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $84.60 | 2019 | |
| Grifols USA, LLC | $79.26 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.01 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $66.18 | 2019-2024 | Arikayce |
| Gilead Sciences, INC. | $51.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $39.44 | 2019 | |
| Genentech USA, INC. | $37.32 | 2019 | |
| Electromed, INC. | $29.20 | 2019 | |
| Nabriva Therapeutics, Plc | $24.45 | 2020 | |
| Jazz Pharmaceuticals INC. | $22.59 | 2019 | |
| United Therapeutics Corporation | $19.44 | 2021 | |
| Pulmonx Corporation | $18.93 | 2024 | Zephyr Delivery Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $18.61 | 2019 | |
| Shire North American Group INC | $15.88 | 2019 | |
| Circassia INC. | $15.49 | 2019 | |
| Mylan Specialty L.P. | $15.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celestino Pietrantoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.